Contineum Therapeutics, Inc. (CTNM): Total Assets
$276.64M
As of 2025-12-31
$250.37M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $276.64M | +30.0% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $212.85M | +63.2% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $130.39M | n/a | 2025-03-06, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $276.64M | +30.0% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $277.17M | +70.2% |
| Annexon, Inc. (ANNX) | 2025-12-31 | $277.57M | -20.7% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $279.93M | +100.9% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $280.41M | -7.7% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $280.73M | -25.5% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $271.15M | -21.2% |
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $282.61M | -22.3% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $284.73M | +59.8% |
Compare CTNM, TNXP, ANNX, ALT side by side · Screen every company in Pharmaceutical Preparations ↗